From: Global assays and the management of oral anticoagulation
 |  | Rivaroxaban | Apixaban | Dabigatran |
---|---|---|---|---|
 |  | In vivo therapeutic dose1 | ||
 | Acute VTE: | 15 mg bid | 10 mg bid | 150 mg bid |
Prophylaxis: | 20Â mg od | 5Â mg bid | 150Â mg bid | |
 |  | In vivo mean plasma concentration (Cmin-Cmax, μg/L)1 | ||
 | Acute VTE: | 100 - 270 | 104 - 330 | 93 - 184 |
Prophylaxis: | 45 - 250 | 50 - 128 | 93 - 184 | |
 |  | In vitro effective concentration (μg/L)2 | ||
PT | – Innovin | 399 ± 49 | >800 | 596 ± 73 |
– Thromborel | 392 ± 36 | >800 | 554 ± 41 | |
– Neoplastin | 214 ± 36 | >800 | 538 ± 47 | |
modified PT | – mPT-Innovin | 43 ± 3 | 190 ± 13 | 64 ± 6 |
– mPT-Thromborel | 47 ± 3 | 80 ± 6 | 88 ± 10 | |
APTT | – Actin FSL | 254 ± 28 | >800 | 190 ± 15 |
TGA | – Lag time | 41 ± 5 | 93 ± 28 | 27 ± 7 |
– Peak thrombin | 109 ± 5 | 121 ± 4 | 380 ± 71 | |
– AUC | 151 ± 36 | 327 ± 99 | 433 ± 71 | |
TEG-TF | – R | 28 ± 3 | 80 ± 17 | 16 ± 8 |
– Angle | 263 ± 66 | 721 ± 73 | 484 ± 3 | |
– MA | >800 | >800 | >800 |